In this Section |
183589 Diversifying the Settings of Opioid Overdose Prevention Trainings: Lessons for ImplementationTuesday, October 28, 2008
Diversifying the Settings of Opioid Overdose Prevention Trainings: Lessons for Implementation
Overdoses are a leading cause of death among opioid users, yet many of these deaths are preventable. Opioid overdose prevention programs train laypersons to carry naloxone (Narcan) for use in reversing suspected overdoses in the community setting, an innovative harm reduction strategy. This intervention began in the United States in the late 1990s and New York City in 2004. It is currently offered in numerous locations around the country using different models depending on the local legal and political environment and available resources. These models will be discussed with a brief review of the components of a concise overdose prevention training. In New York City, these programs were initially implemented in syringe exchange settings, but are now increasingly welcomed in many settings, such as hospitals and community based organizations, that do not traditionally offer harm reduction interventions. Experience in implementing overdose prevention in syringe exchanges and these various other settings will be reviewed. This will include an examination of challenges such as the stigma of overtly providing services for drug users, involving medical personnel, liability issues, concern about promoting drug use and institutional barriers.
Learning Objectives: Keywords: Other Drugs, Prevention
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: I am a New York State-licensed social worker who oversees all of the training and capacity building programs and projects for a community based organization whose mission is to advocate for the health and human rights of substance users - which includes opioid overdose prevention. I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
See more of: From Harm Reduction to Overdose to EBP: A Broad Approach to Treatment
See more of: Alcohol, Tobacco, and Other Drugs |